Menatetrenone
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Summary
Menatetrenone is a form of vitamin K2 which is used in the treatment of osteoporosis to stimulate osteogenesis.
- Generic Name
- Menatetrenone
- DrugBank Accession Number
- DB12148
- Background
Menatetrenone has been used in trials studying the treatment of Diabetes, Osteoporosis, Prediabetic State, and Hepatocellular Carcinoma.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 444.659
Monoisotopic: 444.302830528 - Chemical Formula
- C31H40O2
- Synonyms
- menatetrenona
- Menatetrenone
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Adjunct therapy in management of Osteoporosis •••••••••••• ••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism ACruzipain inhibitorTrypanosoma cruzi - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareOrlistat Orlistat can cause a decrease in the absorption of Menatetrenone resulting in a reduced serum concentration and potentially a decrease in efficacy. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- ATC Codes
- M05BX08 — Menatetrenone
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as menaquinones. These are vitamin K2 compounds consisting of a naphtho-1,4-quinone ring system, which is substituted at the 2-position by an isoprenyl side-chain, and usually, at the 3-position by a methyl group.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Prenol lipids
- Sub Class
- Quinone and hydroquinone lipids
- Direct Parent
- Menaquinones
- Alternative Parents
- Diterpenoids / Naphthoquinones / Quinones / Aryl ketones / Organic oxides / Hydrocarbon derivatives
- Substituents
- Aromatic homopolycyclic compound / Aryl ketone / Benzenoid / Diterpenoid / Hydrocarbon derivative / Ketone / Menaquinone / Naphthalene / Naphthoquinone / Organic oxide
- Molecular Framework
- Aromatic homopolycyclic compounds
- External Descriptors
- menaquinone (CHEBI:78277)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 27Y876D139
- CAS number
- 863-61-6
- InChI Key
- DKHGMERMDICWDU-GHDNBGIDSA-N
- InChI
- InChI=1S/C31H40O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,12,14,16,18-20H,9-11,13,15,17,21H2,1-6H3/b23-14+,24-16+,25-20+
- IUPAC Name
- 2-methyl-3-[(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl]-1,4-dihydronaphthalene-1,4-dione
- SMILES
- [H]\C(CC\C(C)=C(/[H])CC\C(C)=C(/[H])CC1=C(C)C(=O)C2=CC=CC=C2C1=O)=C(\C)CCC=C(C)C
References
- General References
- FDA Thailand Product Information: Glakay (menatetrenone) oral capsules [Link]
- External Links
- Human Metabolome Database
- HMDB0030017
- PubChem Compound
- 5282367
- PubChem Substance
- 347828444
- ChemSpider
- 4445530
- BindingDB
- 50423776
- 29495
- ChEBI
- 78277
- ChEMBL
- CHEMBL259223
- ZINC
- ZINC000003874199
- PDBe Ligand
- 1L3
- Wikipedia
- Menatetrenone
- PDB Entries
- 7f4v
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data4 Completed Treatment Diabetes / Impaired Glucose Tolerance 1 somestatus stop reason just information to hide 4 Completed Treatment Osteoporosis 1 somestatus stop reason just information to hide 2, 3 Terminated Treatment Hepatocellular Carcinoma 1 somestatus stop reason just information to hide 2, 3 Unknown Status Treatment Postmenopausal Osteoporosis 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule 15 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.000489 mg/mL ALOGPS logP 7.24 ALOGPS logP 8.48 Chemaxon logS -6 ALOGPS pKa (Strongest Basic) -7.2 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 34.14 Å2 Chemaxon Rotatable Bond Count 11 Chemaxon Refractivity 145.51 m3·mol-1 Chemaxon Polarizability 54.92 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 220.2000275 predictedDarkChem Lite v0.1.0 [M-H]- 235.4212275 predictedDarkChem Lite v0.1.0 [M-H]- 219.28148 predictedDeepCCS 1.0 (2019) [M+H]+ 220.6737275 predictedDarkChem Lite v0.1.0 [M+H]+ 234.1623275 predictedDarkChem Lite v0.1.0 [M+H]+ 221.2728 predictedDeepCCS 1.0 (2019) [M+Na]+ 220.7149275 predictedDarkChem Lite v0.1.0 [M+Na]+ 235.5432275 predictedDarkChem Lite v0.1.0 [M+Na]+ 227.01323 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsCruzipain
- Kind
- Protein
- Organism
- Trypanosoma cruzi
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Hydrolyzes chromogenic peptides at the carboxyl Arg or Lys; requires at least one more amino acid, preferably Arg, Phe, Val or Leu, between the terminal Arg or Lys and the amino-blocking group.
- Specific Function
- cysteine-type endopeptidase activity
- Gene Name
- Not Available
- Uniprot ID
- P25779
- Uniprot Name
- Cruzipain
- Molecular Weight
- 49835.59 Da
References
- Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]
Drug created at October 20, 2016 21:28 / Updated at August 26, 2024 19:22